NVAXNovavax Inc

CSNasdaq (XNAS)·USD

Identity

Security key: 19400
Ticker: NVAX
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 1995-12-05
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: NVAX

Detail

Enriched 2026-08-14 20:47

Market cap: $1,312,967,978.96
Shares outstanding (class): 164,438,119
Shares outstanding (weighted): 164,945,726
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees: 749
Location: GAITHERSBURG, MD
Homepage: https://www.novavax.com
Description: Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Market cap and share counts drift.

Funds holding this security

89 funds · 89 positions · $231.90M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$41.80M	0.00%	5,135,025 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$38.00M	0.51%	4,667,715 NS	FIGI
VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS	VB	$30.56M	0.02%	3,754,184 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$29.92M	0.04%	3,675,235 NS	FIGI
VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS	VBK	$17.10M	0.04%	2,100,503 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$14.76M	0.02%	1,813,496 NS	FIGI
PIMCO RAE US Small Fund PIMCO Equity Series	—	$10.56M	0.34%	1,297,646 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$9.42M	0.12%	1,157,114 NS	FIGI
iShares Russell 2000 Growth ETF iShares Trust	IWO	$8.20M	0.07%	1,007,699 NS	FIGI
State Street(R) SPDR(R) S&P Kensho New Economie… SPDR SERIES TRUST	KOMP	$3.78M	0.16%	463,799 NS	FIGI
Fidelity Enhanced Small Cap ETF Fidelity Covington Trust	FESM	$3.47M	0.08%	426,160 NS	FIGI
WisdomTree U.S. SmallCap Fund WisdomTree Trust	EES	$2.18M	0.34%	267,369 NS	FIGI
Master Small Cap Index Series Quantitative Master Series LLC	—	$1.99M	0.04%	244,313 NS	FIGI
iShares Core S&P Total U.S. Stock Market ETF iShares Trust	ITOT	$1.96M	0.00%	240,897 NS	FIGI
iShares Russell 2000 Value ETF iShares Trust	IWN	$1.83M	0.01%	224,204 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERNVAX
FIGI_COMPOSITEBBG000NVSBL7
FIGI_SHARE_CLASSBBG001SGL8G3
CIK0001000694
ISINUS6700024010
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Novavax is a biotechnology company developing vaccines, fitting the BIOTECHNOLOGY industry under HEALTHCARE.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.